LOGIN  |  REGISTER
Assertio
Assertio

embecta to Participate in Investor Conferences

May 15, 2023 | Last Trade: US$19.92 0.10 0.50

PARSIPPANY, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced that management will participate in the following investor conferences:

2023 RBC Capital Markets Global Healthcare Conference

  • Management will host a fireside session on Tuesday, May 16, 2023, at 3:05 p.m. Eastern Time (ET) at the InterContinental Barclay, New York. Audio webcasts of the presentations will be accessible under the “News & Events” section of the Company's investor relations website at investors.embecta.com.

2023 Jefferies Global Healthcare Conference

  • Management will host a fireside session on Thursday, Jun 8, 2023, at 3:30 p.m. Eastern Time (ET) at the Marriott Marquis, New York. Audio webcasts of the presentations will be accessible under the “News & Events” section of the Company's investor relations website at investors.embecta.com.

About embecta 

embecta is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.

Contacts:

Media Investors 
Christian Glazar  Pravesh Khandelwal
Sr. Director, Corporate Communications    VP, Head of Investor Relations
908-821-6922 551-264-6547
This email address is being protected from spambots. You need JavaScript enabled to view it.      This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB